Relmada Therapeutics RLMD 深 沪
等待开盘 08-10 09:30:00 美东时间
4.94
-0.430
-8.01%
华盛通- 最 高5.575
- 今 开5.55
- 成交量 210.94万股
- 最 低 4.87
- 昨 收 5.37
- 总市值 14.54万
- 52周最高 8.00
- 市盈率 静 --
- 换手率 7167.02%
- 52周最低 0.59
- 委 比 74.09%
- 总股本 2.94万
- 历史最高 54.00
- 量 比 2.05
- 振 幅 13.13%
- 历史最低 0.2404
- 每 手 1
- 风险率 2.06%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多FDA Approval Positions United Therapeutics To Broaden Access To Donor Lungs
United Therapeutics received FDA approval for LungFX, a device designed to expand donor lung use in transplantation.
06-30 00:50
Relmada's Cancer Drug Candidate Sparks Fresh Bullish Call
HC Wainwright initiates Relmada Therapeutics (NASDAQ: RLMD) with a Buy rating and $12 target, highlighting its bladder cancer potential.
06-19 01:38
Earnings Scheduled For March 19, 2026
Companies Reporting Before The Bell • Neuraxis (AMEX:NRXS) is projected to repo...
03-19 19:11
Why Is Relmada Therapeutics Stock Soaring Monday?
Relmada Therapeutics shares rise on promising interim data from Phase 2 trial of NDV-01 for non-muscle invasive bladder cancer.
03-09 20:48
Market-Moving News for March 9th
HIMS: 54% | Novo Nordisk And Hims & Hers End Bitter Legal Feud With Surprise Weight-Loss Drug Deal: Report RLMD: 80% | Relmada Therapeutics Announces 12-month Interim Data From Its
03-09 19:30
Relmada Therapeutics Announces Private Placement Of $160M
Pursuant to the terms of the securities purchase agreement, Relmada is selling an aggregate of (i) 29,474,569 shares of its common stock ("Common Stock") at a purchase price of $4.75 per share and (ii) pre-funded
03-09 19:16
Earnings Scheduled For November 13, 2025
Companies Reporting Before The Bell • Edgewell Personal Care (NYSE:EPC) is proj...
2025-11-13 19:11
Relmada Therapeutics Appoints Urology Expert Raj S. Pruthi, MD as CMO-Urology
Relmada Therapeutics appoints Raj S. Pruthi, MD as Chief Medical Officer for Urology to lead the development of NDV-01 for non-muscle invasive bladder cancer (NMIBC). Dr. Pruthi, with extensive expertise in urologic oncology and clinical trials, is crucial for advancing NDV-01's Phase 3 trial, expected to begin in H1 2026. Positive Phase 2 data showed promising results with GEM/DOCE sustained release formulation, offering improved response rates and tolerability for NMIBC patients.
2025-06-17 11:00
Jefferies Upgrades Relmada Therapeutics to Buy, Raises Price Target to $13
Jefferies analyst Andrew Tsai upgrades Relmada Therapeutics (NASDAQ:RLMD) from Hold to Buy and raises the price target from $3.5 to $13.
2024-09-17 20:46
Relmada Therapeutics Files For Mixed Shelf Offering Of Up To $250M
Relmada Therapeutics Files For Mixed Shelf Offering Of Up To $250M
2024-08-31 04:30
